Cargando…
Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide
The effects of cytosine phosphoguanine oligodeoxynucleotides (CPG ODNs) on immune response have been demonstrated for different vaccines; however, such information is limited for the vector-based Coronavirus disease 2019 (COVID-19). This paper aims to demonstrate the potential effect of CPG ODNs on...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864427/ https://www.ncbi.nlm.nih.gov/pubmed/36679896 http://dx.doi.org/10.3390/vaccines11010053 |
_version_ | 1784875582099554304 |
---|---|
author | Celise, Divine Ainee Kimotho, James Kimani, Josephine W. Muriithi, Alex Kigundu Odari, Eddy Okoth |
author_facet | Celise, Divine Ainee Kimotho, James Kimani, Josephine W. Muriithi, Alex Kigundu Odari, Eddy Okoth |
author_sort | Celise, Divine Ainee |
collection | PubMed |
description | The effects of cytosine phosphoguanine oligodeoxynucleotides (CPG ODNs) on immune response have been demonstrated for different vaccines; however, such information is limited for the vector-based Coronavirus disease 2019 (COVID-19). This paper aims to demonstrate the potential effect of CPG ODNs on immunological response against the vector-based COVID-19 vaccine on Balb/c mice using a JNJ-78436735 Ad26.COV2-S recombinant as a model vaccine. A total of 18 BALB/c mice clustered into six groups were used. All groups were observed for 14- and 28-days post immunization. Qualitative determination of IgG was performed using indirect Enzyme-Linked Immunosorbent Assay (ELISA) and qPCR for cytokine profiling. A significant (p ≤ 0.001) rise in antibody response was observed for groups 3 and 4, who also showed increased expression levels of Tumor Necrosis Factor (TNF) and Interferon Gamma (IFN-γ). Immunological parameters for toxicity were normal in all treatment groups. We conclude that supplementing vector-based COVID-19 vaccines with CpG ODNs has the potential to boost the body’s immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. |
format | Online Article Text |
id | pubmed-9864427 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98644272023-01-22 Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide Celise, Divine Ainee Kimotho, James Kimani, Josephine W. Muriithi, Alex Kigundu Odari, Eddy Okoth Vaccines (Basel) Article The effects of cytosine phosphoguanine oligodeoxynucleotides (CPG ODNs) on immune response have been demonstrated for different vaccines; however, such information is limited for the vector-based Coronavirus disease 2019 (COVID-19). This paper aims to demonstrate the potential effect of CPG ODNs on immunological response against the vector-based COVID-19 vaccine on Balb/c mice using a JNJ-78436735 Ad26.COV2-S recombinant as a model vaccine. A total of 18 BALB/c mice clustered into six groups were used. All groups were observed for 14- and 28-days post immunization. Qualitative determination of IgG was performed using indirect Enzyme-Linked Immunosorbent Assay (ELISA) and qPCR for cytokine profiling. A significant (p ≤ 0.001) rise in antibody response was observed for groups 3 and 4, who also showed increased expression levels of Tumor Necrosis Factor (TNF) and Interferon Gamma (IFN-γ). Immunological parameters for toxicity were normal in all treatment groups. We conclude that supplementing vector-based COVID-19 vaccines with CpG ODNs has the potential to boost the body’s immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. MDPI 2022-12-26 /pmc/articles/PMC9864427/ /pubmed/36679896 http://dx.doi.org/10.3390/vaccines11010053 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Celise, Divine Ainee Kimotho, James Kimani, Josephine W. Muriithi, Alex Kigundu Odari, Eddy Okoth Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide |
title | Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide |
title_full | Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide |
title_fullStr | Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide |
title_full_unstemmed | Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide |
title_short | Increase in the Immune Response in Balb/c Mice after the Co-Administration of a Vector-Based COVID-19 Vaccine with Cytosine Phosphoguanine Oligodeoxynucleotide |
title_sort | increase in the immune response in balb/c mice after the co-administration of a vector-based covid-19 vaccine with cytosine phosphoguanine oligodeoxynucleotide |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9864427/ https://www.ncbi.nlm.nih.gov/pubmed/36679896 http://dx.doi.org/10.3390/vaccines11010053 |
work_keys_str_mv | AT celisedivineainee increaseintheimmuneresponseinbalbcmiceafterthecoadministrationofavectorbasedcovid19vaccinewithcytosinephosphoguanineoligodeoxynucleotide AT kimothojames increaseintheimmuneresponseinbalbcmiceafterthecoadministrationofavectorbasedcovid19vaccinewithcytosinephosphoguanineoligodeoxynucleotide AT kimanijosephinew increaseintheimmuneresponseinbalbcmiceafterthecoadministrationofavectorbasedcovid19vaccinewithcytosinephosphoguanineoligodeoxynucleotide AT muriithialexkigundu increaseintheimmuneresponseinbalbcmiceafterthecoadministrationofavectorbasedcovid19vaccinewithcytosinephosphoguanineoligodeoxynucleotide AT odarieddyokoth increaseintheimmuneresponseinbalbcmiceafterthecoadministrationofavectorbasedcovid19vaccinewithcytosinephosphoguanineoligodeoxynucleotide |